{"nctId":"NCT00352976","briefTitle":"TBI Dose De-escalation for Fanconi Anemia","startDateStruct":{"date":"2006-05-18","type":"ACTUAL"},"conditions":["Fanconi Anemia"],"count":83,"armGroups":[{"label":"Treatment with TBI","type":"EXPERIMENTAL","interventionNames":["Drug: Cyclophosphamide","Drug: Fludarabine","Procedure: Total Body Irradiation","Procedure: Bone Marrow Transplantation","Drug: Mycophenolate Mofetil","Drug: Sirolimus"]}],"interventions":[{"name":"Cyclophosphamide","otherNames":["cytoxan"]},{"name":"Fludarabine","otherNames":["fludara"]},{"name":"Total Body Irradiation","otherNames":["Radiation Therapy, Therapeutic radiation"]},{"name":"Bone Marrow Transplantation","otherNames":["Stem Cell transplantation"]},{"name":"Mycophenolate Mofetil","otherNames":["MMF"]},{"name":"Sirolimus","otherNames":["Rapamycin"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\nMeeting the definition of standard risk or high risk Fanconi anemia as defined in the next two sections:\n\n* Standard risk patients must be \\<18 years of age with a diagnosis of Fanconi anemia with aplastic anemia (AA), myelodysplastic syndrome without excess blasts, or high risk genotype as defined below:\n\n  * Aplastic anemia is defined as having at least one of the following when not receiving growth factors or transfusions:\n\n    * platelet count \\<20 \\* 10\\^9/L\n    * ANC \\<5 \\* 10\\^8/L\n    * Hemoglobin \\<8 g/dL\n  * Myelodysplastic syndrome (MDS) with multilineage dysplasia with or without chromosomal anomalies\n  * High risk genotype (e.g. IVS-4 or exon 14 FANCC mutations, or BRCA1 or 2 mutations)\n* High risk patients must have one or more of the following high risk features:\n\n  * Advanced MDS (≥ 5% blast) or acute leukemia\n  * Require additional HSCT for graft failure\n  * History at any time of systemic fungal or gram negative infection\n  * Severe renal disease with a creatinine clearance \\<40 mL/min\n  * Age \\> 18 years\n* Very high risk patients must have Advanced MDS (≥ 5% blast) or acute leukemia after initial hematopoietic stem cell transplant (HSCT)\n* Patients must have an appropriate source of stem cells. Patients and donors will be typed for HLA-A, B, C and DRB1 using high resolution molecular typing.\n* Adequate major organ function including:\n\n  * Cardiac: ejection fraction \\>45%\n  * Hepatic: bilirubin, AST or ALT, ALP \\<5 x normal\n  * Karnofsky performance status \\>70% or Lansky \\>50 (if \\< 16 years of age)\n* Women of child-bearing age must be using adequate birth control and have a negative pregnancy test.\n* Written consent.\n\nExclusion Criteria:\n\n* Available HLA-genotypically identical related donor in standard risk patients.\n* Active central nervous system (CNS) leukemia at time of study enrollment.\n* History of squamous cell carcinoma of the head/neck/cervix within previous 2 years.\n* Prior radiation therapy that prevents further total body irradiation (TBI).","healthyVolunteers":false,"sex":"ALL","stdAges":["CHILD","ADULT","OLDER_ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Number of Participant With Neutrophil Recovery","description":"Number of participant with neutrophil recovery. Neutrophil recovery is defined as absolute neutrophil count ≥500/µL for three consecutive days","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"78","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants Experiencing Grade ≥3 Regimen Related Toxicity","description":"Regimen related toxicities (RRT) include: significant hemorrhagic cystitis, pulmonary hemorrhage, interstitial pneumonitis, GI hemorrhage, renal failure, erythroderma, and severe hepatic veno-occlusive disease","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"71","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants With Secondary Graft Failure at 100 Days","description":"Secondary Graft Rejection by day 100","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants Experiencing Acute Graft-versus-host Disease (GVHD)","description":"Number of participants experiencing acute GVHD (all grades) by day 100","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"15","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants Experiencing Chronic GVHD","description":"Number of participants experiencing chronic Graft Vs Host Disease by 1 year","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"6","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants Experiencing Overall Survival","description":"Number of participants experiencing overall survival by 1 year","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"70","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants Experiencing Infections by Day 100","description":null,"paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"53","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants Experiencing Infections by Day 180","description":null,"paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"55","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants Experiencing Infections by Day 365","description":null,"paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"56","spread":null}]}]}]},{"type":"SECONDARY","title":"Average Immunoglobulin G (IgG) Levels as a Measure of Immune Reconstitution After Transplant, by 100 Days","description":null,"paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"550.6","spread":"285.4"}]}]}]},{"type":"SECONDARY","title":"Average IgG Levels as a Measure of Immune Reconstitution After Transplant, by 180 Days","description":null,"paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"652.9","spread":"305.8"}]}]}]},{"type":"SECONDARY","title":"Average IgG Levels as a Measure of Immune Reconstitution After Transplant by 365 Days","description":null,"paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"724.0","spread":"258.0"}]}]}]},{"type":"SECONDARY","title":"Average IgA Levels as a Measure of Immune Reconstitution After Transplant by 100 Days","description":null,"paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"88.0","spread":"59.9"}]}]}]},{"type":"SECONDARY","title":"Average IgA Levels as a Measure of Immune Reconstitution After Transplant by 180 Days","description":null,"paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"98.7","spread":"48.8"}]}]}]},{"type":"SECONDARY","title":"Average IgA Levels as a Measure of Immune Reconstitution After Transplant by 365 Days","description":null,"paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"107.2","spread":"57.0"}]}]}]},{"type":"SECONDARY","title":"Average IgM Levels as a Measure of Immune Reconstitution After Transplant by 100 Days","description":null,"paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"71.1","spread":"84.2"}]}]}]},{"type":"SECONDARY","title":"Average IgM Levels as a Measure of Immune Reconstitution After Transplant by 180 Days","description":null,"paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"77.0","spread":"60.3"}]}]}]},{"type":"SECONDARY","title":"Average IgM Levels as a Measure of Immune Reconstitution After Transplant by 365 Days","description":null,"paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"82.8","spread":"57.9"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":4,"n":83},"commonTop":["Infection","Pneumonia","Cystitis","Hypertension","GI bleed"]}}}